Latest news for Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

AKBA

Biotech

News

Health Care

Movers

General

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval in 37 countries.

FDA Approves For Akebia Therapeutics&#39; Vafseo For Kidney Disease Associated Anemia

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

ABTS

AVTX

CZOO

GCTS

GMDA

HKIT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LGVN

MLKN

MVLA

NCNA

SOBR

UGRO

XXII

Shares of  RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.

Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Intraday Update

ANNX

CTAS

LXRX

MRVL

NCNO

NOAH

NUVB

NVCR

PAYS

SMTC

STKS

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday

Akebia Therapeutics Inc

AKBANK T/A/S GDR 144A by Akbank Turk Anonim Sirketi

Akbank TAS

AKBANK T/A/S S/ADR by Akbank Turk Anonim Sirketi

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Akebia Therapeutics And U.S. Renal Care Announce Collaborative Clinical Trial To Study Vafseo In Kidney Disease Patients, Aiming To Assess Mortality And Hospitalization Compared To Standard Care​

WIIM

Akebia Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $6 to $7.5.

HC Wainwright &amp; Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and raises the price target from $6 to $7.5.

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $7.5

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $43.648 million which missed the analyst consensus estimate of $49.450 million by 11.73 percent. This is a 22.58 percent decrease over sales of $56.376 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Akebia Therapeutics Q2 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $43.648M Miss $49.450M Estimate

<ul>
<li>Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia&#39;s annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million.&nbsp;</li>
<li>Announced&nbsp;Vafseo WAC pricing of $1,278 for a 30-day supply</li>
<li>Submitted&nbsp;TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025</li>
</ul>

Contracts

CSLLY

Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.

Management

Akebia Therapeutics Announced Erik Ostrowski As Senior Vice President, Chief Financial Officer And Chief Business Officer

Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. The company reported quarterly sales of $32.607 million which missed the analyst consensus estimate of $46.087 million by 29.25 percent.&nbsp;

Akebia Therapeutics Q1 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $32.607M Miss $46.087M Estimate

<h3>Gainers</h3>
<ul>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares rose 25.0% to $0.11. The company's market cap stands at $31.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares moved upwards by 24.85% to $2.16. The market value of their outstanding shares is at $1.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 23.06% to $1.39. The market value of their outstanding shares is at $5.6 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 13.96% to $0.24. The company's market cap stands at $2.1 million. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock increased by 11.03% to $1.71. The market value of their outstanding shares is at $358.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares fell 13.0% to $1.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.1 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares fell 10.97% to $1.38. The company's market cap stands at $14.0 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares declined by 8.52% to $4.52. The company's market cap stands at $4.9 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) stock fell 7.12% to $0.4. The market value of their outstanding shares is at $4.3 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock declined by 6.57% to $0.39. The company's market cap stands at $4.4 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares decreased by 6.42% to $26.11. The market value of their outstanding shares is at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ADXN

BPTS

BSGM

COCP

INAB

ISPC

JAGX

SNPX

SXTC

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares moved upwards by 83.33% to $1.43. The company's market cap stands at $10.4 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 81.6% to $1.56. The company's market cap stands at $6.6 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 67.44% to $1.07. The company's market cap stands at $29.4 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares increased by 44.12% to $5.03. The company's market cap stands at $510.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 42.65% to $4.95. The company's market cap stands at $64.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock decreased by 45.4% to $0.18 during Friday's regular session. The company's market cap stands at $10.4 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares decreased by 31.81% to $0.11. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) stock decreased by 29.6% to $5.25. The market value of their outstanding shares is at $275.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 28.84% to $0.58. The company's market cap stands at $6.4 million. The company's, Q4 earnings came out yesterday. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) stock declined by 20.15% to $2.18. The market value of their outstanding shares is at $17.5 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares decreased by 18.09% to $1.83. The company's market cap stands at $384.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

BDRX

MESO

NDRA

PAVM

TNXP

12 Health Care Stocks Moving In Friday's Intraday Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$2.00</td>
<td>$31.2K</td>
<td>6.5K</td>
<td>4.4K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$26.0K</td>
<td>6.2K</td>
<td>559</td>
</tr>
<tr>
<td>EHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$80.00</td>
<td>$48.0K</td>
<td>1.1K</td>
<td>554</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/05/24</td>
<td>$500.00</td>
<td>$142.2K</td>
<td>1.4K</td>
<td>490</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$160.00</td>
<td>$31.0K</td>
<td>523</td>
<td>250</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$450.00</td>
<td>$36.5K</td>
<td>0</td>
<td>159</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$175.00</td>
<td>$52.4K</td>
<td>1.2K</td>
<td>89</td>
</tr>
<tr>
<td>AVDL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$27.0K</td>
<td>185</td>
<td>82</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$260.00</td>
<td>$178.5K</td>
<td>92</td>
<td>79</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$125.00</td>
<td>$35.7K</td>
<td>1.4K</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we notice a put option sweep that happens to be bearish, expiring in 22 day(s) on April 19, 2024. This event was a transfer of 1060 contract(s) at a $2.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.2K, with a price of $30.0 per contract. There were 6593 open contracts at this strike prior to today, and today 4467 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option trade with neutral sentiment. It expires in 85 day(s) on June 21, 2024. Parties traded 500 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $52.0 per contract. There were 6277 open contracts at this strike prior to today, and today 559 contract(s) were bought and sold. 
• For EHC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>), we notice a call option sweep that happens to be bearish, expiring in 22 day(s) on April 19, 2024. This event was a transfer of 160 contract(s) at a $80.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $48.0K, with a price of $300.0 per contract. There were 1185 open contracts at this strike prior to today, and today 554 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bearish sentiment. It expires in 8 day(s) on April 5, 2024. Parties traded 400 contract(s) at a $500.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $142.2K, with a price of $355.0 per contract. There were 1496 open contracts at this strike prior to today, and today 490 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a put option sweep that happens to be bearish, expiring in 85 day(s) on June 21, 2024. This event was a transfer of 10 contract(s) at a $160.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.0K, with a price of $3104.0 per contract. There were 523 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a call option trade that happens to be bearish, expiring in 29 day(s) on April 26, 2024. This event was a transfer of 159 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $36.5K, with a price of $230.0 per contract. There were 0 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option trade with neutral sentiment. It expires in 50 day(s) on May 17, 2024. Parties traded 57 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $52.4K, with a price of $920.0 per contract. There were 1273 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold. 
• Regarding AVDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>), we observe a put option sweep with bearish sentiment. It expires in 295 day(s) on January 17, 2025. Parties traded 52 contract(s) at a $20.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $520.0 per contract. There were 185 open contracts at this strike prior to today, and today 82 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a put option sweep that happens to be bearish, expiring in 295 day(s) on January 17, 2025. This event was a transfer of 79 contract(s) at a $260.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $178.5K, with a price of $2260.0 per contract. There were 92 open contracts at this strike prior to today, and today 79 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a call option trade that happens to be bearish, expiring in 295 day(s) on January 17, 2025. This event was a transfer of 24 contract(s) at a $125.00 strike. The total cost received by the writing party (or parties) was $35.7K, with a price of $1490.0 per contract. There were 1436 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

MRNA

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

HC Wainwright &amp; Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and raises the price target from $5 to $6.

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6

Wednesday, the FDA approved&nbsp;Akebia Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37974236/akebia-receives-fda-approval-of-vafseo-vadadustat-tablets-for-the-treatment-of-anemia-due-to-chron" rel="noreferrer noopener">at least three months</a>.&nbsp;
Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia.&nbsp;
Vafseo is now approved in 37 countries.
The approval of Vafseo is based on efficacy and safety data from the INNO2VATE program and an assessment of post-marketing safety data from Japan, where VAFSEO was launched in August 2020.&nbsp;
Results from the INNO2VATE program were published in the New England Journal of Medicine.&nbsp;
Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to CKD.
Akebia intends to commercialize Vafseo in the U.S. with its established commercial team.&nbsp;
In line with the approved label, Akebia will execute a launch strategy to drive Vafseo toward the goal of becoming a new oral standard of care for adult dialysis patients.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/34073734/analyst-highly-confident-in-akebia-therapeutics-kidney-disease-associated-anemia-drug-stock-soars" rel="noreferrer noopener">Analyst Highly Confident In Akebia Therapeutics&#8217; Kidney Disease-Associated Anemia Drug, Stock Soars</a>.
Citing,&nbsp;H.C. Wainwright&nbsp;analyst, Reuters noted that with an estimated launch of&nbsp;Vafseo&nbsp;in the second half of this year, peak sales are expected to reach $954 million in 2031.
Price Action:&nbsp;AKBA shares are up 18.8% at $2.66 during the premarket session on the last check Thursday.

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Shares of RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) rose sharply in today&rsquo;s pre-market trading following the release of <a href="https://www.benzinga.com/news/earnings/24/03/37971597/rh-q4-earnings-revenue-miss-eps-miss-upbeat-guidance-on-accelerating-demand-trends-and-more">quarterly results</a>.
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
RH shares jumped 9.4% to $324.99 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) rose 256.6% to $16.94 in pre-market trading after the company announced it acquired a Phase 2-ready anti-IL-1&beta; mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio.</li>
<li>Binah Capital Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcg#NASDAQ">BCG</a>) gained 149% to $23.65 in pre-market trading after dipping more than 20% on Wednesday.</li>
<li>Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 49.5% to $4.89 in pre-market trading.</li>
<li>Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares rose 36.3% to $0.1220 in pre-market trading. Kintara Therapeutics announced expansion of REM-001 clinical study to include patients on pembrolizumab.</li>
<li>Cazoo Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NASDAQ">CZOO</a>) gained 32.2% to $16.60 in pre-market trading after jumping over 100% on Wednesday.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akba#NASDAQ">AKBA</a>) shares rose 25% to $2.80 in pre-market trading. Akebia&#39;s received the FDA approval of Vafseo&reg; tablets for dialysis-related anemia treatment.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) gained 17% to $3.66 in pre-market trading. Longeveron&rsquo;s board recently approved a 1-for-10 reverse split of Class A common stock.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) climbed 14.1% to $0.15 in pre-market trading. 22nd Century Group is expected to report quarterly earnings today.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) shares rose 9% to $28.50 in pre-market trading. GigaCloud Technology filed annual report on Form 10-K for fiscal year 2023.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>GCT Semiconductor Holding Inc, (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) dipped 21.2% to $34.68 in pre-market trading amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>MillerKnoll, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlkn#NASDAQ">MLKN</a>) shares fell 17.4% to $25.19 in pre-market trading as the company reported downbeat sales for its third quarter and issued weak guidance for the fourth quarter.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) shares tumbled 16.6% to $0.0494 in pre-market trading. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.</li>
<li>urban-gro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ugro#NASDAQ">UGRO</a>) declined 16.3% to $1.5196 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) fell 15.2% to $0.0640 pre-market trading after dipping 20% on Wednesday.</li>
<li>NuCana plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>) fell 13.4% to $0.2702 in pre-market trading. NuCana announced a plan to implement 1-for-25 ADS ratio change.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares dropped 10% to $26.00 in pre-market trading after the company reported fourth-quarter results. The company also disclosed material weaknesses and remediation plan .</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 9.2% to $0.7083 in pre-market trading.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) fell 8.1% to $1.60 in pre-market trading after gaining over 22% on Wednesday.</li>
<li>SOBR Safe, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sobr#NASDAQ">SOBR</a>) fell 8% to $0.46 pre-market trading after gaining 12% on Wednesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37975718/rh-walgreens-and-3-stocks-to-watch-heading-into-thursday"> RH, Walgreens And 3 Stocks To Watch Heading Into Thursday</a>
&nbsp;

<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 223.94% to $2.07. The market value of their outstanding shares is at $56.9 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 27.1% to $0.21. The company's market cap stands at $1.8 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares rose 23.01% to $0.11. The market value of their outstanding shares is at $4.2 million. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock increased by 18.34% to $2.65. The company's market cap stands at $555.0 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock increased by 16.36% to $1.28. The company's market cap stands at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 19.8% to $0.25 during Thursday's pre-market session. The market value of their outstanding shares is at $13.0 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares declined by 10.51% to $0.34. The company's market cap stands at $4.0 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares declined by 10.48% to $0.15. The market value of their outstanding shares is at $2.3 million. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) stock fell 9.87% to $2.46. The market value of their outstanding shares is at $19.8 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>YS Biopharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YS#NASDAQ">YS</a>) shares decreased by 9.43% to $0.64. The market value of their outstanding shares is at $121.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares declined by 9.0% to $2.53. The company's market cap stands at $14.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IMRN

INVO

SNOA

YTEN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Akebia Therapeutics shares are trading higher after the FDA approved Vafseo tablets for treatment of anemia due to chronic kidney disease in adult patients on dialysis.

<ul>
<li>Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia&nbsp;</li>
<li>Akebia&#39;s Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care</li>
</ul>

Reported Earlier, Akebia's Wins FDA Approval Of Vafseo® Tablets For Dialysis-Related Anemia Treatment

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.
Shares of Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>) rose sharply during Wednesday&rsquo;s session after the company reported better-than-expected third-quarter financial results and <a href="https://www.benzinga.com/quote/CTAS/earnings">raised FY24 guidance</a>.
Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3.59 per share. The company&rsquo;s quarterly sales came in at $2.406 billion, versus expectations of $2.386 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cintas shares climbed 9.7% to $694.62 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>PaySign, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pays#NASDAQ">PAYS</a>) shares jumped 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results.</li>
<li>Noah Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noah#NYSE">NOAH</a>) climbed 17.5% to $11.89 after the company reported fourth quarter financial results.</li>
<li>NuScale Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) gained 17.5% to $4.89.</li>
<li>The ONE Group Hospitality, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stks#NASDAQ">STKS</a>) shares climbed 17.2% to $4.70 after the company announced that it will acquire Safflower Holdings.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/djt#NASDAQ">DJT</a>) climbed 16.7% to $67.68 after jumping 16% on Tuesday.</li>
<li>nCino, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncno#NASDAQ">NCNO</a>) rose 15.2% to $34.78 as the company reported better-than-expected fourth-quarter results and issued FY25 adjusted earnings guidance above estimates..</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) gained 11.6% to $2.22.</li>
<li>Nuvation Bio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NYSE">NUVB</a>) rose 11.3% to $3.2050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.40 to $10.</li>
<li>Annexon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/annx#NASDAQ">ANNX</a>) gained 10.6% to $7.61 following quarterly results.</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) gained 8.6% to $14.19 after the company&#39;s METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial progression for brain metastases from non-small cell lung cancer.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akba#NASDAQ">AKBA</a>) gained 8% to $2.16.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) shares gained 7.8% to $27.12.</li>
<li>Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) rose 5.6% to $72.04.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) gained 5.6% to $3.8650.</li>
<li>Wayfair Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/w#NYSE">W</a>) rose 5.4% to $68.27.</li>
<li>Merck &amp; Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) gained 4.4% to $131.09 after the company received FDA approval for Winrevair (sotatercept) for adults with pulmonary arterial hypertension.</li>
<li>Kohl&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kss#NYSE">KSS</a>) rose 4.1% to $27.36.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37956686/top-3-consumer-stocks-that-may-rocket-higher-this-quarter"> Top 3 Consumer Stocks That May Rocket Higher This Quarter</a>

Shares of Westport Fuel Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wprt#NASDAQ">WPRT</a>) fell sharply during Tuesday&rsquo;s session after posting a wider-than-expected fourth-quarter loss.
Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
Westport Fuel Systems shares dipped 9.9% to $6.52 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stok#NASDAQ">STOK</a>) shares gained 72.6% to $11.24 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) climbed 65% to $0.0581 after the company reported a year-over-year increase in fourth-quarter financial results.</li>
<li>OpGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opgn#NASDAQ">OPGN</a>) shares climbed 48.2% to $0.7039 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) gained 43.2% to $3.1501. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory acute graft versus host disease.</li>
<li>Praxis Precision Medicines Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prax#NASDAQ">PRAX</a>) gained 31.9% to $66.63 after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.</li>
<li>Nuvation Bio Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NYSE">NUVB</a>) climbed 24.4% to $2.80 after BTIG upgraded the stock from Neutral to Buy.</li>
<li>Check-Cap Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chek#NASDAQ">CHEK</a>) shares gained 24.3% to $2.40 after the company announced that it entered into a definitive Business Combination Agreement with Nobul AI.</li>
<li>Viking Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares climbed 23.3% to $85.29 after the company announced results from its Phase 1 multiple ascending dose clinical trial of an oral tablet formulation of VK2735.</li>
<li>Krispy Kreme, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnut#NASDAQ">DNUT</a>) gained 21.3% to $15.10 after the company and McDonald&#39;s expanded their partnership, with Krispy Kreme to provide donuts at McDonald&#39;s locations nationwide.</li>
<li>Journey Medical Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/derm#NASDAQ">DERM</a>) gained 19.9% to $3.50.</li>
<li>Akso Health Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahg#NASDAQ">AHG</a>) climbed 17.5% to $1.21.</li>
<li>9F Inc &ndash; ADR (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) gained 17% to $3.50.</li>
<li>Invivyd, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivvd#NASDAQ">IVVD</a>) gained 17% to $3.78. Morgan Stanley analyst Maxwell Skor upgraded Invivyd from Equal-Weight to Overweight and raised the price target from $4 to $10.</li>
<li>Sunnova Energy International Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) shares gained 16.4% to $6.28 after the company announced that it will be the sole provider of solar and battery storage services in The Home Depot stores across the United States and its territories.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwav#NASDAQ">GWAV</a>) climbed 16.3% to $0.18 after surging 24% on Monday. Greenwave Technology Solutions 13G filing showed Joseph Reda reported a 9.119% stake in the co as of March 22, 2024.</li>
<li>Reddit Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rddt#NYSE">RDDT</a>) climbed 15.8% to $69.26 amid post-IPO volatility.</li>
<li>Canopy Growth Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) shares gained 15.6% to $7.17.</li>
<li>Qurate Retail Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qrteb#NASDAQ">QRTEB</a>) climbed 13.7% to $4.40.</li>
<li>Natural Grocers by Vitamin Cottage Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ngvc#NYSE">NGVC</a>) climbed 13.4% to $19.25.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtp#NASDAQ">SXTP</a>) shares rose 9.8% to $0.2660 after dipping 10% on Monday.</li>
<li>Seagate Technology Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stx#NASDAQ">STX</a>) gained 9.2% to $96.33 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $73 to $115.</li>
<li>McCormick &amp; Company Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkc#NYSE">MKC</a>) climbed 9% to $76.24 after the company reported better-than-expected first-quarter financial results.</li>
<li>IHS Holding Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) climbed 7.6% to $3.74.</li>
<li>Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) gained 5.8% to $182.65 amid reports suggest Italy has approached the company about electric truck production.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quhuo Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qh#NASDAQ">QH</a>) dipped 68.5% to $0.40.</li>
<li>NeuBase Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbse#NASDAQ">NBSE</a>) fell 51.8% to $0.48 after declining around 3% on Monday.</li>
<li>Cardlytics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdlx#NASDAQ">CDLX</a>) dipped 40.4% to $12.06 after the company announced a $150 million proposed convertible senior notes offering.</li>
<li>AppTech Payments Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apcx#NASDAQ">APCX</a>) fell 39.3% to $1.00 after the company priced its 2 million share offering at $1 per share.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares tumbled 27.6% to $0.037 after jumping around 30% on Monday.</li>
<li>Professional Diversity Network Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipdn#NASDAQ">IPDN</a>) fell 27.2% to $1.82.</li>
<li>Canoo Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goev#NASDAQ">GOEV</a>) shares fell 21.4% to $3.30.</li>
<li>GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) fell 20.2% to $6.68 after the company reported fourth-quarter results, disclosed equity raise and new CEO for its international business.</li>
<li>Equillium Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eq#NASDAQ">EQ</a>) shares declined 20.1% to $1.95 following fourth-quarter results.</li>
<li>BYND Cannasoft Enterprises (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 17.9% to $1.61.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares declined 17.9% to $14.78.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) shares dropped 17.8% to $2.08 after the company reported downbeat fourth-quarter results.</li>
<li>Etao International (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) shares fell 14.7% to $4.35.</li>
<li>Tivic Health Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tivc#NASDAQ">TIVC</a>) fell 14.4% to $1.24 after posting fourth-quarter results.</li>
<li>Akebia Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akba#NASDAQ">AKBA</a>) shares dipped 9.5% to $2.00.</li>
<li>Graphjet Technology (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gti#NASDAQ">GTI</a>) fell 9.3% to $7.26.</li>
<li>Monte Rosa Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) dipped 8.4% to $7.75.</li>
<li>Consol Energy Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ceix#NYSE">CEIX</a>) declined 8.1% to $79.36.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) fell 4% to $276.00. Telsey Advisory Group analyst Joseph Feldman reiterated RH with a Market Perform and maintained a $285 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37934560/ethereum-surpasses-3-600-dogwifhat-emerges-as-top-gainer"> Ethereum Surpasses $3,600; dogwifhat Emerges As Top Gainer</a>

APCX

BCAN

CDLX

CEIX

CHEK

CISS

DADA

DERM

DNUT

EGOX

ETAO

GLUE

GOEV

GWAV

IPDN

IVVD

MRNO

NBSE

NGVC

NOVA

OPGN

PRAX

QRTEB

RDDT

STOK

SXTP

TIVC

TSLA

VKTX

WPRT

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Akebia Therapeutics names Erik Ostrowski as CFO

Akebia Therapeutics (AKBA) just unveiled an announcement. Erik Ostrowski has been appointed as the Senior Vice President, CFO, CBO, Treasurer, and ...

Akebia Therapeutics Welcomes New CFO and Financial Strategist

Akebia Therapeutics (AKBA) has provided an announcement. Akebia Therapeutics and CSL Vifor have mutually terminated their exclusive licensing agree...

Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan

Akebia regains full rights to kidney disease therapy from CSL

Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harri...

Buy Rating Justified by Akebia Therapeutics' Strengthened Dialysis Negotiations and Positive Commercial Prospects

Akebia GAAP EPS of -$0.04, revenue of $43.67M

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX – Research Report), Akebia Thera...

Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Akebia Therapeutics: Generics Competition Means Rough Weather Ahead

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), retaining the price target of $7.50. Ed...

Buy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo's Market Launch

AVAH

GOVX

Press Releases

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Akebia Therapeutics

News

Latest news for Akebia Therapeutics (NASDAQ:AKBA) Stock

People Also Watch